Exploring thromboelastography for monitoring anticoagulation in hemodialysis patients
Preliminary Exploration of Thromboelastography in the Monitoring of Anticoagulation in Maintenance Hemodialysis Patients
This study is testing whether a special blood test can help doctors better monitor blood thinning in patients who are on hemodialysis.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | RenJi Hospital Academic / other |
| Locations | 1 site (Shanghai, Shanghai) |
| Trial ID | NCT06272708 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the role of thromboelastography parameters, specifically R, K, Angle, and MA, in monitoring anticoagulation in patients undergoing maintenance hemodialysis. It will involve 200 stable hemodialysis patients and assess the relationship between these thromboelastography parameters and the coagulation of the hemodialysis circuit and dialyzer. The primary outcome focuses on the R Value, while secondary outcomes will explore the other parameters.
Who should consider this trial
Good fit: Ideal candidates are stable hemodialysis patients aged over 18 who have been undergoing treatment for at least 3 months.
Not a fit: Patients with severe diseases such as active malignancy or severe liver diseases, as well as those who are pregnant or lactating, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the monitoring of anticoagulation in hemodialysis patients, potentially improving patient outcomes.
How similar studies have performed: While this approach is innovative, it is not clear if similar studies have shown success, indicating a potential for novel findings.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. male or female patients aged over 18 years 2. stable patients undergoing maintenance hemodialysis treatment for at least 3 months 3. signed informed consent form Exclusion Criteria: 1. concomitant with severe diseases such as active malignancy, severe liver diseases, systemic infection, etc. 2. planned or ongoing pregnancy or lactation 3. unsuitable for inclusion in this study after assessment
Where this trial is running
Shanghai, Shanghai
- Renji Hospital, School of Medicine, Shanghai Jiao Tong University — Shanghai, Shanghai, China (Recruiting)
Study contacts
- Principal investigator: Yiwei Shen, MD — RenJi Hospital
- Study coordinator: Yiwei Shen, MD
- Email: shenyiwei08@126.com
- Phone: 0086-18121099413
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.